CT388-103 was a multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II study conducted in 469 adults with obesity or who are overweight and have at least one weight-related comorbidity, excluding type 2 diabetes
The findings offer new insight into why these medications may influence compulsive behaviors more broadly, raising the possibility that they could eventually help treat conditions tied to addiction and reward processing
Healthcare providers may consider using standardized screening tools such as the PHQ-9 (Patient Health Questionnaire-9) to monitor for depression symptoms during follow-up visits, particularly for patients with pre-existing mental health conditions
Patients can access care through a direct pricing model, avoiding delays associated with approvals
Reduced carbohydrate cravings One of the underappreciated benefits of this combination is how semaglutide makes keto adherence dramatically easier